• If you are wondering whether Danaher stock at around US$183.63 offers fair value or a potential discount, a useful starting point is understanding how its current price lines up against different valuation checks.
• The stock has gained 3.1% over the past week and 10.3% over the past month, yet year to date it is down 20.3% and over the last year it is down 9.7%. This may leave you questioning whether recent moves reflect changing prospects or simply shifting risk appetite.
• Recent coverage has focused on how investors are reassessing large healthcare and life sciences companies in light of shifting capital allocation priorities and ongoing M&A interest across the sector. This context helps frame why a stock like Danaher can see short term swings even while the long term story takes longer to play out.
• Danaher currently has a valuation score of 3 out of 6, which means half of the standard checks flag it as undervalued. The rest of this article will unpack the main valuation approaches investors commonly use, then finish with a way to think about value that goes beyond the usual ratios.

Find out why Danaher's -9.7% return over the last year is lagging behind its peers.

Approach 1: Danaher Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock might be worth by projecting the company’s future cash flows and then discounting them back to today’s value using a required return.

For Danaher, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $5.10b. Analyst and extrapolated projections point to Free Cash Flow of $8.05b in 2030, with a series of annual estimates between 2026 and 2035 that Simply Wall St discounts back to today using its own assumptions.

When all these projected cash flows are added and discounted, the model arrives at an estimated intrinsic value of about $224.01 per share. Compared with the current share price of around $183.63, this points to an 18.0% discount, which indicates Danaher stock screens as undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Danaher is undervalued by 18.0%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Danaher.

Approach 2: Danaher Price vs Earnings

For profitable companies, the P/E ratio is a useful way to connect what you pay per share with the earnings the business is currently generating. It gives you a quick sense of how many dollars investors are willing to pay today for each dollar of current earnings.

What counts as a "normal" P/E depends a lot on expectations and risk. Higher expected earnings growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually lines up with a lower one.

Danaher currently trades on a P/E of 35.37x. That sits above the Life Sciences industry average of about 34.23x, yet below the broader peer group average of 38.43x. Simply Wall St also uses a proprietary "Fair Ratio" of 29.29x, which is the P/E it would expect for Danaher after accounting for factors such as earnings growth, profit margins, industry, market cap and company specific risks.

This Fair Ratio is more tailored than a simple comparison with peers or the industry because it adjusts for Danaher’s own characteristics rather than assuming all companies deserve the same multiple. With the current P/E of 35.37x above the Fair Ratio of 29.29x, the stock screens as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Danaher Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and on Simply Wall St that means using Narratives. These are short, clear stories that you and other investors build around Danaher by linking your view of its business drivers to specific forecasts for future revenue, earnings and margins. The platform then converts those into a fair value and compares that fair value with the current price to help decide whether the stock looks attractive or expensive. It will also automatically refresh that view as new news or earnings arrive. In this framework, the bullish Narrative might look closer to the higher analyst fair value around US$310, while a more cautious Narrative might sit nearer the lower end around US$200. All of this is available for you to explore and adjust on the Community page without needing to build a full model from scratch.

Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.